Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network.
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network.
复制标题
DOI：
10.1038/s41375-020-01016-0
复制
发表时间：
2021-01
期刊：
影响因子：
11.4
通讯作者：
Sonneveld P
中科院分区：
文献类型：
--
作者：
Ludwig H;Boccadoro M;Moreau P;San-Miguel J;Cavo M;Pawlyn C;Zweegman S;Facon T;Driessen C;Hajek R;Dimopoulos MA;Gay F;Avet-Loiseau H;Terpos E;Zojer N;Mohty M;Mateos MV;Einsele H;Delforge M;Caers J;Weisel K;Jackson G;Garderet L;Engelhardt M;van de Donk N;Leleu X;Goldschmidt H;Beksac M;Nijhof I;Abildgaard N;Bringhen S;Sonneveld P
疫苗接种是最成功的医疗干预措施之一，挽救了数百万人的生命。疫苗接种在多发性骨髓瘤患者中尤其重要，由于疾病固有的免疫抑制以及治疗的免疫抑制作用，多发性骨髓瘤患者的感染风险增加。因此，应采取所有适当的措施，以引起对常见病原体（如流感、肺炎球菌、水痘带状疱疹病毒）以及经常可能对多发性骨髓瘤患者构成重大风险的细菌和病毒（流感嗜血杆菌、脑膜炎球菌和肝炎）的有效免疫应答。自体移植后，特别是同种异体移植后的患者抗体滴度严重降低，因此需要更广泛的疫苗接种。骨髓瘤患者对疫苗接种的反应通常不如一般人群强烈，因此需要测量疫苗接种后的抗体滴度和/或重复接种。在这里，我们汇编了多发性骨髓瘤疫苗接种的现有数据，并为临床实践提供建议。
Vaccination is one of the most successful medical interventions that has saved the life of millions of people. Vaccination is particularly important in patients with multiple myeloma, who have an increased risk of infections due to the disease-inherent immune suppression, and because of the immune suppressive effects of therapy. Hence, all appropriate measures should be exploited, to elicit an effective immune response to common pathogens like influenza, pneumococci, varicella zoster virus, and to those bacteria and viruses (haemophilus influenzae, meningococci, and hepatitis) that frequently may pose a significant risk to patients with multiple myeloma. Patients after autologous, and specifically after allogeneic transplantation have severely reduced antibody titers, and therefore require a broader spectrum of vaccinations. Response to vaccination in myeloma often is less vigorous than in the general population, mandating either measurement of the postvaccination antibody titers and/or repeating the vaccination. Here, we compile the existing data on vaccination in multiple myeloma and provide recommendations for clinical practice.
登录
查看更多内容
影响因子：
11.8
作者：
Cordonnier, Catherine;Labopin, Myriam;Ljungman, Per
通讯作者：
Ljungman, Per
影响因子：
56.3
作者：
Cordonnier, Catherine;Einarsdottir, Sigrun;Wenneras, Christine
通讯作者：
Wenneras, Christine
影响因子：
5.5
作者：
Hartkamp, A;Mulder, AHL;Biesma, DH
通讯作者：
Biesma, DH
影响因子：
4
作者：
Bahuaud M;Bodilis H;Malphettes M;Maugard Landre A;Matondo C;Bouscary D;Batteux F;Launay O;Fermand JP
通讯作者：
Fermand JP
DOI：
10.1016/j.clml.2018.10.002
发表时间：
2019-01
期刊：
Clinical lymphoma, myeloma & leukemia
影响因子：
--
作者：
Frerichs KA;Bosman PWC;Nijhof IS;Zweegman S;van de Donk NWCJ
通讯作者：
van de Donk NWCJ